J84.8
Conditions
Interventions
Group 1: • Demographic data: age, sex, body mass index (BMI), smoking status, and relevant pre-existing conditions
• Pulmonary function diagnostics: spirometry to assess vital capacity and forced expi
body plethysmography to measure airway resistance and lung volumes
diffusion capacity (DLCO) to evaluate gas exchange
• Imaging: high-resolution computed tomography (HRCT) for structural assessment of lung parenchyma
• Laboratory parameters: including inflammatory ma
Sponsors
Kliniken der Stadt Köln, Lungenklinik
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Systemic autoimmune diseases with interstitial lung disease
Exclusion criteria
Exclusion criteria: Age <18 years ILD of another cause Missing informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The progression of SARD-associated interstitial lung disease (SARD-ILD), as measured by the criteria for progressive pulmonary fibrosis (PPF) according to the guidelines by Raghu G. et al., 2022. | — |
Secondary
| Measure | Time frame |
|---|---|
| Collection and analysis of pulmonary function parameters as well as demographic and clinical data to characterize the patient group with SARD-ILD. This includes the following: • Handgrip strength (HGS) • K-BILD questionnaire to assess health-related quality of life • High-resolution computed tomography of the lungs (HRCT) • Clinical auscultation findings (e.g., crackles) • Laboratory parameters related to disease activity • 6-minute walk test (6MWT) to assess functional exercise capacity | — |
Countries
Germany
Contacts
Public ContactSarah Bettina Stanzel
Kliniken der Stadt Köln, Lungenklinik
Outcome results
None listed